

Trillium Therapeutics Inc (TRIL) - Financial and Strategic SWOT Analysis Review

<https://marketpublishers.com/r/TA95D88F9E4EN.html>

Date: May 2021

Pages: 45

Price: US\$ 125.00 (Single User License)

ID: TA95D88F9E4EN

Abstracts

Trillium Therapeutics Inc (TRIL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description – A detailed description of the company's operations and business divisions.

Corporate strategy – Analyst's summarization of the company's business strategy.

SWOT Analysis – A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history – Progression of key events associated with the company.

Major products and services – A list of major products, services and brands of the company.

Key competitors – A list of key competitors to the company.

Key employees – A list of the key executives of the company.

Executive biographies – A brief summary of the executives' employment history.

Key operational heads – A list of personnel heading key departments/functions.

Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.

Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Trillium Therapeutics Inc (Trillium), formerly Neurogenesis Biotech Corp, is a clinical stage immuno-oncology company, which develops novel therapies for the treatment of cancer. The company uses biologic and small molecule-based approaches to develop its portfolio. Its lead program, TTI-621 (intravenous), a SIRPaFc fusion protein is evaluated for the treatment of B and T-cell lymphomas and also for other blood cancers. Trillium is also developing TTI-621 (intratumoral) for solid cancers and T

cell lymphomas; TTI-622 for lymphoma and myeloma; and small molecule STING agonist TTI -10001 for cancers. Trillium is headquartered in Cambridge, Massachusetts, the US.

Trillium Therapeutics Inc Key Recent Developments

May 07,2021: Trillium Therapeutics Reports First Quarter 2021 Operating and Financial Results

Apr 22,2021: Trillium Therapeutics to host virtual R&D day for investors on April 28, 2021

Mar 18,2021: Trillium Therapeutics Reports Annual Operating and Financial Results

and Sets Date for R&D Day

Nov 16,2020: Trillium Therapeutics reports third quarter 2020 financial and operating results

Nov 12,2020: Trillium Therapeutics appoints Paolo Pucci to its Board of Directors

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

Trillium Therapeutics Inc - Key Facts
Trillium Therapeutics Inc - Key Employees
Trillium Therapeutics Inc - Key Employee Biographies
Trillium Therapeutics Inc - Major Products and Services
Trillium Therapeutics Inc - History
Trillium Therapeutics Inc - Company Statement
Trillium Therapeutics Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
Trillium Therapeutics Inc - Business Description
Trillium Therapeutics Inc - Corporate Strategy
Trillium Therapeutics Inc - SWOT Analysis
SWOT Analysis - Overview
Trillium Therapeutics Inc - Strengths
Trillium Therapeutics Inc - Weaknesses
Trillium Therapeutics Inc - Opportunities
Trillium Therapeutics Inc - Threats
Trillium Therapeutics Inc - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Trillium Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD

2021

Trillium Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD

2021

Trillium Therapeutics Inc, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

May 07, 2021: Trillium Therapeutics Reports First Quarter 2021 Operating and Financial Results

Apr 22, 2021: Trillium Therapeutics to host virtual R&D day for investors on April 28, 2021

Mar 18, 2021: Trillium Therapeutics Reports Annual Operating and Financial Results and Sets Date for R&D Day

Nov 16, 2020: Trillium Therapeutics reports third quarter 2020 financial and operating results

Nov 12, 2020: Trillium Therapeutics appoints Paolo Pucci to its Board of Directors

Nov 02, 2020: Trillium Therapeutics announces formation of Scientific Advisory Board

Nov 02, 2020: Trillium Therapeutics appoints Dr. Ingmar Bruns as Chief Medical Officer

Oct 05, 2020: Trillium Therapeutics receives notices of allowance from U.S. Patent and Trademark Office

Sep 18, 2020: Trillium Therapeutics appoints Michael Kamarck, Ph.D., to its board of directors

Aug 12, 2020: Trillium Therapeutics reports second quarter 2020 financial and operating results

SECTION 6 – APPENDIX

Methodology

Ratio Definitions

About GlobalData

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Trillium Therapeutics Inc, Key Facts
Trillium Therapeutics Inc, Key Employees
Trillium Therapeutics Inc, Key Employee Biographies
Trillium Therapeutics Inc, Major Products and Services
Trillium Therapeutics Inc, History
Trillium Therapeutics Inc, Other Locations
Trillium Therapeutics Inc, Subsidiaries
Trillium Therapeutics Inc, Key Competitors
Trillium Therapeutics Inc, Ratios based on current share price
Trillium Therapeutics Inc, Annual Ratios
Trillium Therapeutics Inc, Annual Ratios (Cont...1)
Trillium Therapeutics Inc, Interim Ratios
Trillium Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Trillium Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Trillium Therapeutics Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

Trillium Therapeutics Inc, Performance Chart (2016 - 2020)

Trillium Therapeutics Inc, Ratio Charts

Trillium Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021

Trillium Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021

I would like to order

Product name: Trillium Therapeutics Inc (TRIL) - Financial and Strategic SWOT Analysis Review

Product link: <https://marketpublishers.com/r/TA95D88F9E4EN.html>

Price: US\$ 125.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/TA95D88F9E4EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970